{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Cancer&page=4", "query": { "condition": "Fallopian Cancer", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 691, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Cancer&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Cancer&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T07:31:41.517Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05985655", "title": "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Pancreatic Adenocarcinoma", "Non-small Cell Lung Cancer (NSCLC)", "Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)", "Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "GTAEXS617", "type": "DRUG" }, { "name": "SoC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-07-06", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 6, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05985655" }, { "nct_id": "NCT01294293", "title": "TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Ovarian Mixed Epithelial Tumor", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "TLR8 Agonist VTX-2337", "type": "DRUG" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2011-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-12-25", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Iowa City, Iowa + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01294293" }, { "nct_id": "NCT00053833", "title": "S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 2, "start_date": "2003-04", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2013-11-08", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 99, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053833" }, { "nct_id": "NCT00004064", "title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "oregovomab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AltaRex", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 102, "start_date": "1998-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 15, "location_summary": "Newport Beach, California • Fort Myers, Florida • Orlando, Florida + 11 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004064" }, { "nct_id": "NCT05295589", "title": "Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Ovarian Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Platinum-Resistant Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2022-06-30", "completion_date": "2023-03-17", "has_results": false, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 5, "location_summary": "Aurora, Colorado • Iowa City, Iowa • Cleveland, Ohio + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05295589" }, { "nct_id": "NCT04028479", "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma", "Adenocystic Carcinoma", "Anal Cancer", "Appendix Cancer", "Brain Tumor", "Glioblastoma", "Astrocytoma", "Bile Duct Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Bone Cancer", "Synovial Sarcoma", "Chondrosarcoma", "Liposarcoma", "Sarcoma, Kaposi", "Sarcoma,Soft Tissue", "Sarcoma", "Osteosarcoma", "CNS Cancer", "Brain Stem Neoplasms", "Breast Cancer", "Cervical Cancer", "Colorectal Cancer", "Rectal Cancer", "Colon Cancer", "Esophageal Cancer", "Esophagus Cancer", "Cancer of Colon", "Pancreatic Cancer", "Cancer of Pancreas", "Testis Cancer", "Testicular Cancer", "Ureter Cancer", "Renal Cell Carcinoma", "Kidney Cancer", "Gestational Trophoblastic Tumor", "Head and Neck Neoplasms", "Parotid Tumor", "Larynx Cancer", "Tongue Cancer", "Pharynx Cancer", "Salivary Gland Cancer", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Multiple Myeloma", "Non Hodgkin Lymphoma", "Carcinoid Tumor", "Lung Cancer", "Neuroendocrine Tumors", "Mesothelioma", "Thyroid Cancer", "Parathyroid Neoplasms", "Adrenal Cancer", "Small Bowel Cancer", "Stomach Cancer", "Liver Cancer", "Hepatic Cancer", "Melanoma", "Skin Cancer", "Unknown Primary Tumors", "Uterine Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Prostate Cancer", "Vaginal Cancer", "Penile Cancer", "Vulvar Cancer", "Waldenstrom Macroglobulinemia", "Cancer, Advanced", "Thymus Cancer", "Nasopharyngeal Carcinoma", "Multiple Endocrine Neoplasia", "Pheochromocytoma", "Small Cell Carcinoma", "Pulmonary Carcinoma" ], "interventions": [ { "name": "Biomarker Testing (L)", "type": "DIAGNOSTIC_TEST" }, { "name": "Systemic Treatment (T)", "type": "DRUG" }, { "name": "Patient Reported Outcomes (P)", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG", "OTHER" ], "sponsor": "Taproot Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2021-05-05", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 2, "location_summary": "Idaho Falls, Idaho • Laredo, Texas", "locations": [ { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Laredo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028479" }, { "nct_id": "NCT00253383", "title": "Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "counseling intervention", "type": "OTHER" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2003-01", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • White River Junction, Vermont", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253383" }, { "nct_id": "NCT06342986", "title": "Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gynecologic Cancer", "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "FT536", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "CY", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2024-07-11", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06342986" }, { "nct_id": "NCT01652079", "title": "CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "CRLX101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 63, "start_date": "2012-04", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652079" }, { "nct_id": "NCT02478476", "title": "DNA Single Nucleotide Polymorphisms as Predictors of Toxicity", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "OvaGene Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 75, "start_date": "2015-07", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-10-22T07:31:41.517Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02478476" } ] }